Aydın, YusufErden, MücahitErmiş, FatihKutlucan, AliKaya, ErtuğrulAydın, Leyla YılmazCelbek, Gökhan2020-04-302020-04-3020130393-63842283-9720https://hdl.handle.net/20.500.12684/3992Kaya, Ertugrul/0000-0003-0081-682XWOS: 000330151200043Aims: To determine the effects of diabetes mellitus (DM) treatment regimens on malignancy. Methods: Six hundred fifty-five DM patients were enrolled. Patients receiving diabetes therapies for at least one year were retrospectively assessed with physical examination, detailed medical, habits, demographic characteristics and laboratory tests, and divided into two groups according to the diabetes treatment type (using oral agent or insulin and using metformin or not). Insulin users were grouped according to insulin regimens (intensive, basal and mixed) and to the insulin type (glargine, detemir, human insulin, biphasic analogue). Cancer cases were identified at the first visit. Results: Among 655 DM patients 13 (2%) were Type 1 DM, 642 (98%) were Type 2 DM; 379 (58%) were female, 276 (42%) were male. Thirty-sir cancers and 76 benign tumors were observed. Patients with and without a cancer were compared for diabetes treatment regimens and types of agents. No significant differences were observed between groups using oral agent or insulin (p=0.429) and using metformin or not (p=0.119). There were no significant differences between groups according to insulin regimens (p=0.059) and the insulin type (p=0.418). Conclusion: There was no significant difference in terms of cancer risk between different types of pharmacological treatments of diabetes (including analog insulins).eninfo:eu-repo/semantics/closedAccessDiabetes mellituscancerinsulininsulin glarginemetforminoral antidiabeticsArticle294859867WOS:000330151200043N/AQ4